March 27, 2025 – Eli Lilly expanded its LillyDirect platform to offer connections to independent in-person and telehealth providers for people in the United States living with Alzheimer’s disease. The new initiative is aimed at improving the diagnostic rates of Alzheimer’s disease as well as enhancing patient access to treatment options.
The expansion aligns with the company’s broader commitment to advancing Alzheimer’s research and treatment accessibility. According to Alzheimer’s Association, about 7 million Americans are living with Alzheimer’s, and this number is expected to rise to nearly 13 million by 2050.
With the growing incidence of Alzheimer’s disease in the U.S. and other nations, early diagnosis is crucial for effective disease management. The inclusion of telehealth services within LillyDirect will allow patients to consult specialists without geographic limitations.
Lily’s new initiative will address challenges like limited access to specialists and extended wait times for patients. It will significantly improve access to timely diagnosis and treatment for individuals with memory and thinking issues. The company also aims to boost sales of its drug Kisunla (donanemab) through the new expansion.
Eli Lilly’s inclusion of telehealth services for Alzheimer’s disease through its LillyDirect platform is expected to positively impact the Alzheimer’s diagnostics and therapeutics industry. This initiative could lead to increased adoption of therapies like Kisunla by facilitating early diagnosis and treatment initiation.
According to Coherent Market Insights (CMI), the global Alzheimer’s disease diagnostics and therapeutics market size is set to total US$ 10,543 million by 2032. Overall demand for Alzheimer’s disease diagnostic and therapeutic solutions will likely increase at 5.4% CAGR during the forecast period.
“Early diagnosis and treatment can make a huge difference for people suffering from Alzheimer’s disease. As a result, companies like Eli Lilly are introducing new initiatives and solutions to help patients identify and access additional independent specialty care capacity,” says a senior analyst at CMI.”
Online platforms, such as Lilly’s, can provide educational resources and screening tools that encourage early detection of Alzheimer’s disease. Thanks to these platforms, more individuals may seek diagnosis and treatment sooner, leading to high demand for diagnostic tests and therapeutics.
Lilly’s updated platform offers tools like Healthgrade doctor locator, which helps users find clinicians experienced in diagnosing and managing Alzheimer’s disease. Moreover, it will connect patients to Synapticure, a provider specializing in neurodegenerative care.
Other companies are expected to follow Lilly’s suit by offering telehealth services for Alzheimer’s disease diagnosis and management. This will eventually boost growth of the global Alzheimer’s disease diagnostics and therapeutics industry during the forthcoming period.
Sources:
News Outlet: Reuters
Company: Eli Lilly and Company
